Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- Government Perspectives on Mobility and the Cloud
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Reimagining the Next Generation of Government
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
Merck replacing R&D head with former company exec
Thursday - 3/7/2013, 5:19pm EST
LINDA A. JOHNSON
AP Business Writer
Merck & Co. said Thursday that it's getting a new director of research and development, Dr. Roger M. Perlmutter, a former research executive at Merck and at Amgen Inc.
Merck, the world's third-biggest drugmaker by revenue, said Perlmutter will begin running Merck Research Laboratories on April 15.
He'll succeed Peter S. Kim, 55, who's overseen the labs since 2003. The two will work together initially, then Kim will serve as an adviser until leaving Merck on Aug. 1.
Steven Cragle, a spokesman for the Whitehouse Station, N.J., company, said the moves are part of long-term succession planning by CEO Kenneth C. Frazier and are unrelated to some recent failures of experimental drugs Merck had been testing.
Perlmutter, 60, served as executive vice president and head of research and development at Amgen from January 2001 to February 2012. During that stretch, he oversaw development of several new pills and biologic drugs for cancer, endocrine and blood disorders, osteoporosis and inflammation.
Many of those areas are key ones for Merck, which has long been a leader in osteoporosis and cardiac medicines but has struggled in its efforts to develop biosimilar drugs. Those are medicines that are like, but not exactly identical to, biologic drugs, injected medicines that are produced in living cells rather than by mixing chemicals together, the way pills are made.
There are no biosimilar drugs approved in the U.S. yet, but they are expected to hit the market in the next several years. Because they will be somewhat cheaper than biologic drugs, which can cost tens of thousands of dollars a year, patients and health plans are eager for that.
Perlmutter, who holds medical and doctoral degrees from Washington University in St. Louis, was a professor and chairman of the Department of Immunology at the University of Washington before coming to Merck in February 1997. He served there as a senior vice president and then executive vice president of basic research and preclinical development, or laboratory and animal testing. He then moved to Amgen.
Kim likewise was a professor early in his career, teaching biology at Massachusetts Institute of Technology. Under his tenure at Merck, the company developed more than 20 new drugs and vaccines. Those include Victrelis for hepatitis C, type 2 diabetes pill Januvia, HIV drug Isentress and the Gardasil vaccine against sexually transmitted diseases.
"Peter always felt that he would have a third chapter in his professional life," but hasn't disclosed his plans, Cragle said.
Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.